186 related articles for article (PubMed ID: 34865635)
1. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma.
Buendía JA; Patiño DG
BMC Pulm Med; 2021 Dec; 21(1):398. PubMed ID: 34865635
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma.
Buendía JA; Patiño DG
BMC Pulm Med; 2021 Dec; 21(1):397. PubMed ID: 34865628
[TBL] [Abstract][Full Text] [Related]
3. Tiotropium for children and adolescents with severe asthma.
Antonio Buendía J; Patiño DG
J Asthma; 2023 May; 60(5):1009-1015. PubMed ID: 36047659
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility of azithromycin in patients with severe asthma.
Buendía JA; Patiño DG; Feliciano-Alfonso JE
J Asthma; 2022 Oct; 59(10):2008-2015. PubMed ID: 34516322
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.
Wilson EC; Price D; Musgrave SD; Sims EJ; Shepstone L; Murdoch J; Mugford HM; Blyth A; Juniper EF; Ayres JG; Wolfe S; Freeman D; Gilbert RF; Hillyer EV; Harvey I
Pharmacoeconomics; 2010; 28(7):597-608. PubMed ID: 20446755
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
7. SMART therapy in adolescent and adults patients with moderate persistent asthma: a cost-utility analysis.
Buendía JA; Patiño DG
J Asthma; 2022 Dec; 59(12):2367-2374. PubMed ID: 34913809
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
9. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model.
Paltiel AD; Fuhlbrigge AL; Kitch BT; Liljas B; Weiss ST; Neumann PJ; Kuntz KM
J Allergy Clin Immunol; 2001 Jul; 108(1):39-46. PubMed ID: 11447380
[TBL] [Abstract][Full Text] [Related]
11. Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma.
Buendia JA; Guerrero Patiño D; Cossio-Giraldo YE
J Asthma; 2022 Oct; 59(10):2016-2023. PubMed ID: 34551659
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D supplementation for children with mild to moderate asthma: an economic evaluation.
Antonio Buendía J; Patiño DG; Lindarte EF
J Asthma; 2023 Sep; 60(9):1668-1676. PubMed ID: 36755388
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists.
Willson J; Bateman ED; Pavord I; Lloyd A; Krivasi T; Esser D
Appl Health Econ Health Policy; 2014 Aug; 12(4):447-59. PubMed ID: 24974107
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility of tiotropium in patients with severe asthma.
Buendía JA; Patiño DG
Cost Eff Resour Alloc; 2024 Jan; 22(1):4. PubMed ID: 38238836
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility of as-needed combination low-dose budesonide-formoterol in adolescents mild asthma.
Buendía JA; Guerrero Patiño D; Talamoni HL
Pediatr Pulmonol; 2021 Dec; 56(12):3699-3705. PubMed ID: 34473917
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
